Friday, 28 Feb 2020

You are here

Health Canada Issues Acetaminophen Advisory

Yesterday Health Canada announced it “is taking additional steps to minimize the risk of liver damage and improve acetaminophen safety,” citing the findings of a government review that underscored the possibility of accidental overdose.

Of the 4 billion doses of acetaminophen sold in Canada each year, there were 4000 hospitalizations for acetaminophen overdose - 20% of these were using doses in excess of 4000 mg per day. A Statistics Canada database recorded 253 accidental deaths and nearly 300 suicides between 2000 and 2009 where acetaminophen was a major or contributing cause of death.

Acetaminophen By the Numbers

4 billion — Number of doses of acetaminophen sold in Canada each year

475 — The number of different acetaminophen products currently authorized for marketing in Canada

4 — Number of grams of acetaminophen in the recommendation maximum daily dose

10 — Number of grams of acetaminophen per day that can lead to liver damage

4,000 — Number of hospitalizations in Canada each year for acetaminophen overdose

20 — Percentage of hospitalizations for acetaminophen overdose due to people exceeding the recommended dose unintentionally

250 — Number of cases of serious liver injury per year in Canada related to acetaminophen

50 — Percentage of cases of serious liver injury associated with unintentional overdoses


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Overmedication of America

Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly. 

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

No Cancer Risk with Systemic Necrotizing Vasculitis

The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.

Previous reports have suggested either no risk or a declining risk in the era of better therapies for vasculitis. 

FDA Warns 15 CBD Manufacturers

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).  This warning affirms that the FDA has not determined the many preparations of cannabidiol to be safe or effective.